-
公开(公告)号：US20240075116A1
公开(公告)日：2024-03-07
申请号：US18183082
申请日：2023-03-13
申请人： CureVac SE
CPC分类号： A61K39/0011 , A61K39/001103 , A61K39/001104 , A61K39/001106 , A61K39/001107 , A61K39/001109 , A61K39/001119 , A61K39/001122 , A61K39/001139 , A61K39/00114 , A61K39/00115 , A61K39/001151 , A61K39/001156 , A61K39/001157 , A61K39/001158 , A61K39/00116 , A61K39/001162 , A61K39/001166 , A61K39/001168 , A61K39/001182 , A61K39/001184 , A61K39/001186 , A61K39/001188 , A61K39/00119 , A61K39/001191 , A61K39/001193 , A61K39/001194 , A61K39/001195 , A61P35/00 , A61K2039/53
摘要： The present invention relates to an RNA encoding a tumor antigen. In particular, the present invention relates to RNA suitable for treatment and/or prophylaxis of cancer and related diseases. The present invention concerns such RNA as well as compositions, vaccines and kits comprising the RNA. Furthermore, the present invention relates to the RNA, compositions, vaccines or kits as disclosed herein for use in the treatment and/or prophylaxis of cancer and related diseases.
-
公开(公告)号：US11911359B2
公开(公告)日：2024-02-27
申请号：US14531469
申请日：2014-11-03
发明人： Weihsu Chen , Weili Yan , Kenya Johnson , Gregory Conn , Frank Bedu-Addo , Leaf Huang
IPC分类号： A61K31/231 , A61K31/20 , A61K39/00 , A61K39/39 , A61K47/64 , A61K31/14 , A61K39/12 , A61K45/06 , C07C219/06
CPC分类号： A61K31/231 , A61K31/14 , A61K31/20 , A61K39/00 , A61K39/0011 , A61K39/12 , A61K39/39 , A61K45/06 , A61K47/646 , C07C219/06 , A61K2039/55555
摘要： The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.
-
公开(公告)号：US11896666B2
公开(公告)日：2024-02-13
申请号：US17195003
申请日：2021-03-08
申请人： Zoetis Services LLC
发明人： Paul Joseph Dominowski , Ramasamy Mannar Mannan , Richard Lee Krebs , James Richard Thompson , Tedd Alan Childers , Mary Kathryn Olsen , Robert John Yancey, Jr. , Risini Dhammika Weeratna , Shucheng Zhang , Cedo Martin Bagi
IPC分类号： A61K39/39 , A61K39/012 , A61K39/108 , A61K39/12 , A61K39/145 , A61K39/00 , A61K39/02 , A61K39/15 , A61K39/21 , A61K39/215 , A61P37/02 , A61K39/002
CPC分类号： A61K39/39 , A61K39/002 , A61K39/0011 , A61K39/012 , A61K39/0208 , A61K39/0241 , A61K39/0258 , A61K39/12 , A61K39/145 , A61K39/15 , A61K39/21 , A61K39/215 , A61P37/02 , A61K2039/521 , A61K2039/5252 , A61K2039/5254 , A61K2039/54 , A61K2039/55 , A61K2039/552 , A61K2039/55505 , A61K2039/55511 , A61K2039/55555 , A61K2039/55561 , A61K2039/55566 , A61K2039/55572 , A61K2039/55577 , C12N2720/12334 , C12N2720/12351 , C12N2740/13034 , C12N2740/13051 , C12N2760/16134 , C12N2760/16151 , C12N2770/20034 , C12N2770/20051 , C12N2770/24334 , C12N2770/24351 , Y02A50/30
摘要： This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.
-
64.发明公开公开(公告)号：US20240041998A1
公开(公告)日：2024-02-08
申请号：US18350454
申请日：2023-07-11
申请人： Memorial Sloan-Kettering Cancer Center , Memorial Hospital for Cancer and Allied Diseases , Sloan-Kettering Institute for Cancer Research
IPC分类号： A61K39/00 , A61K39/395 , A61P35/00
CPC分类号： A61K39/0011 , A61K39/3955 , A61P35/00 , A61K2039/5252 , A61K2039/585
摘要： The present disclosure relates generally to methods for sensitizing PRC2 mutant tumors to immune checkpoint blockade therapy in a subject in need thereof comprising administering to the subject an effective amount of inactivated modified vaccinia virus Ankara (MVA) or MVA ΔE3L.
-
公开(公告)号：US11890332B2
公开(公告)日：2024-02-06
申请号：US17073656
申请日：2020-10-19
发明人： Jae Yun Kim , Nguyen Thanh Loc
CPC分类号： A61K39/0011 , A61K9/143 , A61K9/5115 , A61K47/02 , A61K47/6923 , A61K2039/5152 , A61K2039/5154 , A61K2039/55555
摘要： The present invention relates to a dual-scale porous silica particle-based pharmaceutical composition for preventing or treating cancer, which includes porous silica nanoparticles and porous silica microparticles. The pharmaceutical composition of the present invention promotes the generation of a larger amount of antigen-specific, cytotoxic T cells against cancer than a mesoporous silica nanoparticle (MSN) vaccine, and exhibits increased anti-tumor efficacy compared with a mesoporous silica microrod (MSR) vaccine.
-
66.发明公开公开(公告)号：US20240033333A1
公开(公告)日：2024-02-01
申请号：US18021373
申请日：2021-08-13
发明人： Farhad DASTMALCHI , Maryam RAHMAN , Thomas Ettor ANGELINI , Hector R. MENDEZ-GOMEZ , Elias SAYOUR
CPC分类号： A61K39/0011 , A61P35/00 , A61K2039/55522 , A61K2039/6093 , A61K2039/6018 , A61K2039/53
摘要： The present disclosure includes biocompatible, nanocomposite hydrogel compositions and vaccines, where the compositions and vaccines include a biocompatible hydrogel material, a plurality of immune stimulating cytokines, such as CXCL9, and a plurality of nano liposomes loaded with mRNA molecules corresponding to a target antigen, such as for a condition to be treated. This disclosure also includes methods of making the biocompatible, nanocomposite hydrogel compositions and vaccines as well as methods of using the vaccines of the present disclosure to treat and/or prevent a disease in a subject.
-
公开(公告)号：US20240024705A1
公开(公告)日：2024-01-25
申请号：US18478342
申请日：2023-09-29
申请人： The Regents of the University of Michigan , The United States Government as represented by the Department of Veterans Affairs
发明人： Zhen XU , Clifford Suhyun CHO
CPC分类号： A61N7/00 , A61K39/0011 , A61B10/0045
摘要： Systems and methods for histotripsy and immunotherapy are provided. In some embodiments, histotripsy can be applied to a target tissue volume to lyse and solubilize the target tissue volume to release tumor antigens. In some embodiments, an immune response of the treatment can be evaluated. In other embodiments, an immune therapy can be applied after applying the histotripsy. In one embodiment, the lysed and solubilized cells can be extracted from the tissue. The extracted cells can be used to create immune therapies, including vaccines.
-
68.发明公开公开(公告)号：US20240016913A1
公开(公告)日：2024-01-18
申请号：US18458233
申请日：2023-08-30
发明人： Jens HUKELMANN , Heiko SCHUSTER , Ricarda HANNEN , Christoph SCHRAEDER , Jens FRITSCHE , Franziska HOFFGAARD , Daniel Johannes KOWALEWSKI , Oliver SCHOOR
IPC分类号： A61K39/00 , A61P35/00 , C07K14/705 , C07K14/74
CPC分类号： A61K39/0011 , A61P35/00 , C07K14/705 , C07K14/70539 , A61K39/00 , A61K2039/5158
摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
69.发明公开公开(公告)号：US20240016910A1
公开(公告)日：2024-01-18
申请号：US18455683
申请日：2023-08-25
发明人： Jens HUKELMANN , Heiko SCHUSTER , Ricarda HANNEN , Christoph SCHRAEDER , Jens FRITSCHE , Franziska HOFFGAARD , Daniel Johannes KOWALEWSKI , Oliver SCHOOR
IPC分类号： A61K39/00 , A61P35/00 , C07K14/705 , C07K14/74
CPC分类号： A61K39/0011 , A61P35/00 , C07K14/705 , C07K14/70539 , A61K39/00 , A61K2039/5158
摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240009286A1
公开(公告)日：2024-01-11
申请号：US18234902
申请日：2023-08-17
发明人： Ravid STRAUSSMAN , Oded SANDLER , Reut RIFF
IPC分类号： A61K39/00 , A61K39/395 , A61P35/00
CPC分类号： A61K39/0011 , A61K39/3955 , A61P35/00 , A61K2039/523 , A61K2039/522
摘要： A vaccine comprising tumor-homing bacteria which are genetically modified to express at least one cancer-associated antigen and a pharmaceutically acceptable carrier is disclosed. Uses thereof are also disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
7152 条记录 (耗时 0.035 秒)
